Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a
single intravenous (IV) infusion to patients with moderate or severe immediately
life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A
or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of
single dose of AVM0703 in these ARDS patients.